全身性エリテマトーデス(SLE)の世界市場インサイト・疫学分析・市場予測

◆英語タイトル:Systemic Lupus Erythematosus Market Insight, Epidemiology and Market Forecast
◆商品コード:DELV803017
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:128
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD6,250 ⇒換算¥687,500見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD12,500 ⇒換算¥1,375,000見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD18,750 ⇒換算¥2,062,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Systemic Lupus Erythematosus (SLE) – Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SLE in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Systemic Lupus Erythematosus (SLE) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Systemic Lupus Erythematosus- Disease Understanding and Treatment Algorithm
The DelveInsight Systemic Lupus Erythematosus market report gives the thorough understanding of the Systemic Lupus Erythematosus by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Systemic Lupus Erythematosus in the US, Europe, and Japan.

Systemic Lupus Erythematosus Epidemiology
The Systemic Lupus Erythematosus (SLE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, Lupus Nephritis prevalent cases, diagnosed cases and treatable cases) scenario of Systemic Lupus Erythematosus (SLE) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of prevalent and diagnosed population of Systemic Lupus Erythematosus (SLE) was found to be more than 5, 76,232 and 850,000 in 7MM respectively, in the year 2016.

Systemic Lupus Erythematosus Drug Chapters
This segment of the Systemic Lupus Erythematosus report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
More than five decades ago, an antimalarial drug, Plaquenil (Hydrochloroquine; Sanofi-Aventis) was approved by USFDA in 1955 for the treatment of SLE. Since then, no drug received approval for SLE treatment until 2011, when GlaxoSmithKline came up with first ever targeted therapy for the treatment of SLE, Benlysta (Belimumab). Detailed chapter for Benlysta, along with the upcoming therapies i.e., Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Atacicept (Merck KgaA), IFNα KINOID (Neovacs), Vobarilizumab (Ablynx-Abbvie), CC-220 (Celgene) and Ustekinumab (Janssen Research & Development) have been covered in the report.

Systemic Lupus Erythematosus Market Outlook
The Systemic Lupus Erythematosus market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Systemic Lupus Erythematosus in 7MM was found to be more than USD 720 million in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.

Systemic Lupus Erythematosus Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Systemic Lupus Erythematosus Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Systemic Lupus Erythematosus Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Systemic Lupus Erythematosus Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Systemic Lupus Erythematosus market
• Organize sales and marketing efforts by identifying the best opportunities for Systemic Lupus Erythematosus market
• To understand the future market competition in the Systemic Lupus Erythematosus market.

【レポートの目次】

1. Report Introduction 1
2. Systemic Lupus Erythematosus (SLE) Market Overview at a Glance 2
2.1. Market Share Distribution of Systemic Lupus Erythematosus (SLE) in 2017 2
2.2. Market Share Distribution of Systemic Lupus Erythematosus (SLE) in 2027 2
2.3. Total Prevalent Cases of Systemic Lupus Erythematosus (SLE) – by Country (2017) 3
2.4. Total Market by Region of Systemic Lupus Erythematosus (SLE) (2017 & 2027) 3
3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE) 10
3.1. Introduction 10
3.2. Risk Factors 10
3.3. Causes 11
3.4. Symptoms 12
3.5. Clinical Manifestations 13
3.6. Pathogenesis 17
3.7. Diagnosis 19
4. Epidemiology and Patient Population 26
4.1. Key Findings 26
4.2. Population and Forecast Parameters 27
4.3. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM 28
4.4. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – By Region 29
4.5. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – Distribution (2017) 30
4.6. Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM – Distribution (2027) 30
5. Epidemiology of Systemic Lupus Erythematosus (SLE) 31
5.1. United States 31
5.1.1. Assumptions and Rationale 31
5.1.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in United States 33
5.1.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United States 34
5.1.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in United States 35
5.1.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in United States 36
5.1.6. Prevalence of Lupus Nephritis (LN) in United States 37
5.2. Germany 38
5.2.1. Assumptions and Rationale 38
5.2.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) (AK) in Germany 39
5.2.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany 40
5.2.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany 41
5.2.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Germany 42
5.2.6. Prevalence of Lupus Nephritis (LN) in Germany 43
5.3. France 44
5.3.1. Assumptions and Rationale 44
5.3.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in France 45
5.3.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France 46
5.3.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in France 47
5.3.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in France 48
5.3.6. Prevalence of Lupus Nephritis (LN) in France 49
5.4. Italy 50
5.4.1. Assumptions and Rationale 50
5.4.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy 51
5.4.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy 52
5.4.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy 53
5.4.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Italy 54
5.4.6. Prevalence of Lupus Nephritis (LN) in Italy 55
5.5. Spain 56
5.5.1. Assumptions and Rationale 56
5.5.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain 57
5.5.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain 58
5.5.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain 59
5.5.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Spain 60
5.5.6. Prevalence of Lupus Nephritis (LN) in Spain 61
5.6. United Kingdom 62
5.6.1. Assumptions and Rationale 62
5.6.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in United Kingdom 63
5.6.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United Kingdom 64
5.6.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in United Kingdom 65
5.6.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in United Kingdom 66
5.6.6. Prevalence of Lupus Nephritis (LN) in United Kingdom 67
5.7. Japan 68
5.7.1. Assumptions and Rationale 68
5.7.2. Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan 70
5.7.3. Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan 71
5.7.4. Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan 72
5.7.5. Sex-Specific Prevalence of Systemic Lupus Erythematosus (SLE) in Japan 73
5.7.6. Prevalence of Lupus Nephritis (LN) in Japan 74
6. Treatment Practices 75
6.1. Treatment Goals 75
6.2. Treatment Algorithm 76
7. Unmet Needs 80
8. Marketed Drugs 82
8.1. Benlysta: GlaxoSmithKline plc 82
8.1.1. Drug Description 82
8.1.2. Mechanism of Action 82
8.1.3. Regulatory Milestones 82
8.1.4. Advantages & Disadvantages 84
8.1.5. Safety and Efficacy of Benlysta 84
8.1.6. Product Profile 85
9. Emerging Therapies 86
9.1. Key Cross Competition 86
9.2. Phase III Drugs 91
9.2.1. Lupuzor: Immupharma 91
9.2.1.1. Regulatory Milestones 91
9.2.1.2. Other development activities 91
9.2.1.3. Clinical Development 92
9.2.1.4. Clinical Trials Information 92
9.2.1.5. Safety and Efficacy 93
9.2.1.6. Product Profile 93
9.2.2. Anifrolumab: AstraZeneca 94
9.2.2.1. Regulatory Milestones 94
9.2.2.2. Other development activities 94
9.2.2.3. Clinical Development 94
9.2.2.4. Clinical Trials Information 95
9.2.2.5. Safety and Efficacy 96
9.2.2.6. Product Profile 96
9.3. Phase II Drugs 97
9.3.1. Atacicept: Merck KgaA 97
9.3.1.1. Other development activities 97
9.3.1.2. Clinical Development 98
9.3.1.3. Clinical Trials Information 98
9.3.1.4. Safety and Efficacy 99
9.3.1.5. Product Profile 99
9.3.2. IFNα Kinoid: Neovacs 100
9.3.2.1. Regulatory Milestones 100
9.3.2.2. Other development activities 100
9.3.2.3. Clinical Development 100
9.3.2.4. Clinical Trials Information 101
9.3.2.5. Safety and Efficacy 101
9.3.2.6. Product Profile 101
9.3.3. Vobarilizumab: Ablynx 102
9.3.3.1. Other development activities 102
9.3.3.2. Clinical Development 103
9.3.3.3. Clinical Trials Information 103
9.3.3.4. Safety and Efficacy 104
9.3.3.5. Product Profile 104
9.3.4. CC-220: Celgene 105
9.3.4.1. Clinical Development 105
9.3.4.2. Clinical Trials Information 105
9.3.4.3. Safety and Efficacy 106
9.3.4.4. Product Profile 106
9.3.5. STELARA (ustekinumab): Janssen Research & Development 107
9.3.5.1. Clinical Development 108
9.3.5.2. Clinical Trials Information 108
9.3.5.3. Safety and Efficacy 108
9.3.5.4. Product Profile 109
10. Market Size of Systemic Lupus Erythematosus for 7MM 110
10.1. SLE Market Share by Therapies for 7MM 111
10.2. United States-SLE Market Size 112
10.3. EU-5-SLE Market Size 116
10.3.1. Germany-SLE Market Size 117
10.3.2. France-SLE Market Size 118
10.3.3. Italy-SLE Market Size 119
10.3.4. Spain-SLE Market Size 120
10.3.5. United Kingdom-SLE Market Size 121
10.4. Japan-SLE Market Size 122
11. Market Drivers 123
12. Market Barriers 124
13. Appendix 125
14. Report Methodology 125
14.1. Sources Used 125
15. DelveInsight Capabilities 127
16. Disclaimer 128
17. About DelveInsight 128

Table 1: Major clinical manifestations of Systemic Lupus Erythematosus (SLE) 13
Table 2: THE 1982 REVISED CRITERIA FOR CLASSIFICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS 19
Table 3: Differential Diagnosis of Systemic Lupus Erythematosus 20
Table 4: Diagnostic Criteria for Systemic Lupus Erythematosus 22
Table 5: Diagnostic Tests for Systemic Lupus Erythematosus 24
Table 6: Total Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7 MM (2016-2027) 28
Table 7: Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM (2016-2027) 29
Table 8: Prevalent Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027) 33
Table 9: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027) 34
Table 10: Treatable Population of Systemic Lupus Erythematosus (SLE) in United States (2016-2027) 35
Table 11: Sex-Specific Distribution of Systemic Lupus Erythematosus (SLE) in United States (2017) 36
Table 12: Prevalent Population of Lupus Nephritis (LN) in United States (2016-2027) 37
Table 13: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 39
Table 14: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 40
Table 15: Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 41
Table 16: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Germany (2017) 42
Table 17: Prevalent Population of Lupus Nephritis (LN) in Germany (2016-2027) 43
Table 18: Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 45
Table 19: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 46
Table 20: Treatable Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 47
Table 21: Sex-Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2017) 48
Table 22: Prevalent Population of Lupus Nephritis (LN) in France (2016-2027) 49
Table 23: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 51
Table 24: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 52
Table 25: Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 53
Table 26: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Italy (2017) 54
Table 27: Prevalent Population of Lupus Nephritis (LN) in Italy (2016-2027) 55
Table 28: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 57
Table 29: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 58
Table 30: Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 59
Table 31: Sex-Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2017) 60
Table 32: Prevalent Population of Lupus Nephritis (LN) in Spain (2016-2027) 61
Table 33: Prevalent Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 63
Table 34: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 64
Table 35: Treatable Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 65
Table 36: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in UK (2017) 66
Table 37: Prevalent Population of Lupus Nephritis (LN) in United Kingdom (2016-2027) 67
Table 38: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 70
Table 39: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 71
Table 40: Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 72
Table 41: Sex-Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Japan (2017) 73
Table 42: Prevalent Population of Lupus Nephritis (LN) in Japan (2016-2027) 74
Table 43: Comparison of emerging drugs under development 86
Table 44: Comparison of emerging drugs under development 87
Table 45: Emerging drugs: Safety and Efficacy 87
Table 46: Lupuzor, Clinical Trial Description, 2018 92
Table 47: Anifrolumab, Clinical Trial Description, 2018 95
Table 48: Atacicept, Clinical Trial Description, 2018 98
Table 49: Lupuzor, Clinical Trial Description, 2018 101
Table 50: ALX0061, Clinical Trial Description, 2018 103
Table 51: CC-220, Clinical Trial Description, 2018 105
Table 52: Lupuzor, Clinical Trial Description, 2018 108
Table 53: Market Size of Systemic Lupus Erythematosus (SLE) in 7MM in USD, Million (2016-2027) 110
Table 54: US Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 115
Table 55: Germany Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 117
Table 56: France Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 118
Table 57: Italy Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 119
Table 58: Spain Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 120
Table 59: UK Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 121
Table 60:Japan Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 122


Figure 1: Risk Factors of SLE 13
Figure 2: Pathogenesis of Systemic Lupus Erythematosus 20
Figure 3: Algorithm for diagnosis of Systemic Lupus Erythematosus 25
Figure 4: Total Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7 MM (2016-2027) 30
Figure 5: Prevalent Population of Systemic Lupus Erythematosus (SLE) in 7MM (2016-2027) 31
Figure 6: Prevalent Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027) 35
Figure 7: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027) 36
Figure 8:Treatable Population of Systemic Lupus Erythematosus (SLE) in US (2016-2027) 37
Figure 9: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in US (2017) 38
Figure 10: Prevalent Population of Lupus Nephritis in United States (2016-2027) 39
Figure 11: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 41
Figure 12: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 42
Figure 13:Treatable Population of Systemic Lupus Erythematosus (SLE) in Germany (2016-2027) 43
Figure 14: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Germany (2017) 44
Figure 15: Prevalent Population of Lupus Nephritis in Germany (2016-2027) 45
Figure 16: Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 47
Figure 17: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 48
Figure 18:Treatable Population of Systemic Lupus Erythematosus (SLE) in France (2016-2027) 49
Figure 19: Sex- Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in France (2017) 50
Figure 20: Prevalent Population of Lupus Nephritis in France (2016-2027) 51
Figure 21: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 53
Figure 22: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 54
Figure 23:Treatable Population of Systemic Lupus Erythematosus (SLE) in Italy (2016-2027) 55
Figure 24: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Italy (2017) 56
Figure 25: Prevalent Population of Lupus Nephritis in Italy (2016-2027) 57
Figure 26: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 59
Figure 27: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 60
Figure 28:Treatable Population of Systemic Lupus Erythematosus (SLE) in Spain (2016-2027) 61
Figure 29: Sex- Specific Prevalent Population of Systemic Lupus Erythematosus (SLE) in Spain (2017) 62
Figure 30: Prevalent Population of Lupus Nephritis in Spain (2016-2027) 63
Figure 31: Prevalent Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 65
Figure 32: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 66
Figure 33:Treatable Population of Systemic Lupus Erythematosus (SLE) in UK (2016-2027) 67
Figure 34: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in UK (2017) 68
Figure 35: Prevalent Population of Lupus Nephritis in United Kingdom (2016-2027) 69
Figure 36: Prevalent Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 72
Figure 37: Diagnosed Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 73
Figure 38:Treatable Population of Systemic Lupus Erythematosus (SLE) in Japan (2016-2027) 74
Figure 39: Sex- Specific Prevalent Distribution of Systemic Lupus Erythematosus (SLE) in Japan (2017) 75
Figure 40: Prevalent Population of Lupus Nephritis in Japan (2016-2027) 76
Figure 41: Market Size of Systemic Lupus Erythematosus (SLE) in 7MM, in USD, Million (2016-2027) 112
Figure 42: US Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 117
Figure 43: Germany Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 119
Figure 44: France Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 120
Figure 45: Italy Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 121
Figure 46: Spain Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 122
Figure 47: UK Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 123
Figure 48: Japan Market Size of Systemic Lupus Erythematosus (SLE) in USD, Million (2016-2027) 124
Figure 49: Market Drivers 125
Figure 50: Market Barriers 126


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 全身性エリテマトーデス(SLE)の世界市場インサイト・疫学分析・市場予測(Systemic Lupus Erythematosus Market Insight, Epidemiology and Market Forecast )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆